“With our third fund, we will continue to fuel the growth and advancement of medicines by providing capital, strategic guidance, and invaluable expertise to companies developing cutting-edge solutions and to weather the ups and downs of market cycles,” said Christine Brennan, PhD, Managing Director, Boston.
With a focus on the long term, VVHC has an emphasis on improving diversity at the Board and C-suite and to develop teams that are well positioned for success. Individually and together, they possess deep combined investing and operational experience, having led numerous investments in companies that have exited through mergers and acquisitions (M&A) or initial public offerings (IPO). VVHC is anchored by a science-first, diversified investment strategy and is led by Managing Directors Lori Hu and Christine Brennan. “As one of the few women-led funds in the healthcare sector, we are proud of our track record of success in supporting visionary entrepreneurs from company formation through exit.” “As technology continues to reshape industries and science continues to advance, VVHC recognizes the tremendous potential of companies that hold promise for transforming healthcare and driving societal impact,” said Lori Hu, Managing Director, San Francisco.
Fund III will be deployed to support and empower groundbreaking life sciences and medical technology companies aiming to drive innovation and improve patient outcomes. Vertex Ventures HC (VVHC), a women-led global healthcare investment firm, is excited to announce the launch of its third and largest fund of $200 million.
SAN FRANCISCO & BOSTON–(BUSINESS WIRE)–June 26, 2023–
0 kommentar(er)
